SCHOTT Pharma
€24.55Change from previous close: +0.82%Absolute change: +€0.20
At a glance
- Revenue growth
- +3.04%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −2.16%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 14.9%
- FY to Sep 2024: 15.6%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 |
|---|---|---|---|---|
| Total revenue | 986 | 957 | 899 | 821 |
| Cost of revenue | 654 | 634 | 582 | 525 |
| Gross profit | 332 | 323 | 316 | 296 |
| Selling, general and administrative | 130 | 124 | 122 | 110 |
| Research and development | 27.9 | 24.3 | 26.8 | 23.5 |
| Operating income | 187 | 190 | 171 | 169 |
| EBIT | 208 | 197 | 193 | 161 |
| EBITDA | 287 | 262 | 245 | 216 |
| Interest expense | 20.0 | 13.5 | 7.3 | 2.7 |
| Pre-tax income | 188 | 184 | 186 | 158 |
| Income tax | 40.8 | 33.6 | 33.9 | 32.4 |
| Net income | 146 | 150 | 152 | 125 |
| Net income to common shareholders | 146 | 150 | 152 | 125 |
| Basic EPS | 0.97 | 0.99 | 1.01 | 0.83 |
| Diluted EPS | 0.97 | 0.99 | 1.01 | 0.83 |
| Average shares (basic) | 151 | 151 | 151 | 151 |
| Average shares (diluted) | 151 | 151 | 151 | 151 |